The future of chronic myeloid leukemia is evolving

By Giora Sharf | Jun 08, 2016
Giora Sharf is a ph cml patient and co founder of the cml advocates network
Giora Sharf (pictured above) is a Ph+ CML patient and co-founder of the CML Advocates Network, which connects more than 100 patient organizations in almost 80 countries.

Chronic Myeloid Leukemia (CML) is a unique disease within oncology. While thankfully, as a result of targeted treatments, it isn’t a disease most CML patients will die from anymore, there is a passion and dedication from the medical community, patients and caregivers to continue advancing how CML is treated.

When I was first diagnosed with CML 16 years ago, my life expectancy was only three to four years. There were only two treatment options available at that time for CML patients: a medication known for causing severe side effects or a bone marrow transplant. I, along with many other CML patients, felt like I was living in the dark. I didn’t see a future with CML, and while with medication I could live longer, I wasn’t sure it was the life I wanted.

Myeloid leukemia is evolving

A change in two chromosomes, 9 and 22, results in the Philadelphia chromosome, an abnormality seen in almost all CML patients.

Since my diagnosis, first and second generation tyrosine kinase inhibitors (TKIs) have been introduced. These treatments target the specific cause of the disease, and have been a great advancement in the treatment of Ph+ CML as well as in modern medicine. Novartis Oncology has been at the forefront of the transformation of CML from a life-threatening disease to a chronic condition when managed with appropriate treatment in most patients.

In addition to the medical and pharmaceutical communities continuing to research CML to learn more about the disease and also about future treatment options, patients are continuing their education. At the time of my diagnosis, I went to 3 different CML physicians, each of them told me something different about how I should treat the disease. Here I was ― a newly diagnosed patient with no knowledge and no experience, so I decided to learn about CML to help myself, but this evolved into a passion for helping other patients educate themselves. And that was how I became a patient advocate.

Patient advocates play an important role in learning about scientific advances and sharing those learnings with CML patients around the world. I go to medical meetings with fellow advocates and write reports about what I learn. The reports are translated into many languages so patients can learn for themselves about the latest scientific advances.

The CML patient community is eager to see innovation drive new treatment advancements for CML patients and many people I meet ask ‘what’s next in CML?’ I’m excited about companies, like Novartis Oncology, that continue to conduct research and development relating to the treatment of CML, including new treatments and the possibility of treatment-free remission. These potential advances are still under investigation, however I am eager to see what advancements may come from continued research in CML.

Today I’m proud to be a leader in CML. I think about when I was first diagnosed with CML and was told I may only have a few years to live. I am thankful every day that I have benefited from the scientific advances over the last nearly two decades of CML research. I look forward to continuing to witness the ongoing evolution of CML as investigators work to improve the lives of CML patients.

Stopping CML treatment is currently not a clinical recommendation and should only be attempted in the context of a clinical study